Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease

Arabul M., GÜLLÜLÜ M., YILMAZ Y., Akdag I., Kahvecioglu S., Eren M. A., ...More

CLINICAL BIOCHEMISTRY, vol.41, no.13, pp.1055-1058, 2008 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 41 Issue: 13
  • Publication Date: 2008
  • Doi Number: 10.1016/j.clinbiochem.2008.05.010
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1055-1058
  • Bursa Uludag University Affiliated: Yes


Objectives: Anemia, low-grade inflammation and/or alterations in lipid metabolism are common findings in individuals with end-stage renal disease (ESRD) despite advances in dialysis treatment. Hepcidin, a key regulator of iron metabolism, may play an important role in the interdependence of inflammation and anemia in ESRD patients. Statins may reduce cardiovascular events in dialysis patients and have pleiotropic effects in addition to lowering total and low-density lipoprotein (LDL)-cholesterol.